Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

Overview of attention for article published in Frontiers in oncology, April 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

老年晚期NSCLC患者PD-1/PD-L1免疫检查点抑制剂治疗现状及展望

Article in Chinese Journal of Lung Cancer (May 2024)

Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis

Article in Translational Cancer Research (May 2024)

Effectiveness of PD1/PD-L1 combined with anti-angiogenic drugs in patients with advanced nonsmall cell lung cancer: A systematic review and meta-analysis

Article in Journal of Research in Medical Sciences (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.